THE ELITE HAVE ALREADY FFED OFF TO THEIR HIDEOUTS, THEY HAVE RELEASED THE GENOCIDE
READ IT AND WEEP, WE ARE EFFED. PFIZER’S OWN DOCUMENTS STATE BOTH INHALATION AND SKIN CONTACT WILL TRANSMIT WHATEVER IS IN THE VAX FROM THE VACCINATED TO THE UNVACCINATED
. Here is what just this small portion of this Pfizer document is saying:
1. If a man who was not vaccinated touches a vaccinated woman, or breathes any of the air she breathes, (in other words, walks by her in the office) and he then has sex with his wife, his wife can have an adverse event and she should avoid having children. 2. If a woman who was never vaccinated gets exposed to a woman who was vaccinated, she can: A: miscarry, B: spontaneously abort, C. poison a baby via her breast milk D: have babies that have cognitive difficulties.
This is universal, and very bad. Here is a small section of text I translated to English:
188.8.131.52. Occupational Exposure “An occupational exposure occurs when a person receives unplanned direct contact with a vaccine test subject, which may or may not lead to the occurrence of an adverse event. These people may include health care providers, family members, and other people who are around the trial participant.
When such exposures happen, the investigator must report them to Pfizer safety within 24 hours of becoming aware of when they happened, regardless of whether or not there is an associated secondary adverse event. This must be reported using the vaccine secondary adverse event report form. SINCE THE INFORMATION DOES NOT PERTAIN TO A PARTICIPANT INVOLVED IN THE STUDY, THE INFORMATION WILL BE KEPT SEPARATE FROM THE STUDY.”
TO CLARIFY: Vaccine study participants become super spreaders of something, they don’t say what it is, but it triggers secondary adverse events in people that never had the vax, when they are exposed to people who did have the vax.
THIS IS SO BAD that right here, in this little bit of quoted text, it warns that un-vaccinated men who have been exposed to a woman who was vaxxed will then pass whatever is in the vax to another woman.
Even the relatively small portion of the document I have put below here says the vax triggers spontaneous abortions and reproductive problems when un-vaccinated people are exposed to the vaccinated and that breast milk from a vaccinated mom can harm the infant. And if anyone does not believe it, then click the link above and wade through that enormous and intentionally confusing document. It’s for real folks, the vax is indeed the kill shot. Do not permit the vaccinated to come anywhere near you, it is now official.
Here is a small portion of this huge document, straight from pfizer: Terms: Study intervention – A vaccine test subject. AE – Adverse event in someone who got the vax. SAE: An adverse event in someone who was exposed to someone who got the vax. EDP: Exposure during pregnancy
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure Exposure to the study intervention under study during pregnancy or breastfeeding and occupational exposure are reportable to Pfizer Safety within 24 hours of investigator awareness.
184.108.40.206. Exposure During Pregnancy An EDP occurs if: * A female participant is found to be pregnant while receiving or after discontinuing study intervention. * A male participant who is receiving or has discontinued study intervention exposes a female partner prior to or around the time of conception. * A female is found to be pregnant while being exposed or having been exposed to study intervention due to environmental exposure. Below are examples of environmental exposure during pregnancy: * A female family member or healthcare provider reports that she is pregnant after having been exposed to the study intervention by inhalation or skin contact. * A male family member or healthcare provider who has been exposed to the study intervention by inhalation or skin contact then exposes his female partner prior to or around the time of conception.
If this vax is not shedding into other people, why would contact between vaccinated and un-vaccinated be an event worth noting? If this vax is not shedding, then WHY does a guy who has been around a vaccinated woman, even if he did not touch her or have sex, need to worry about getting a different woman pregnant?
That’s not all, the following is detailed, and far worse.
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s awareness, irrespective of whether an SAE has occurred. The initial information submitted should include the anticipated date of delivery (see below for information related to termination of pregnancy).
* If EDP occurs in a participant or a participant’s partner, the investigator must report this information to Pfizer Safety on the Vaccine SAE Report Form and an EDP Supplemental Form, regardless of whether an SAE has occurred. Details of the pregnancy will be collected after the start of study intervention and until 6 months after the last dose of study intervention.
* If EDP occurs in the setting of environmental exposure, the investigator must report information to Pfizer Safety using the Vaccine SAE Report Form and EDP Supplemental Form. Since the exposure information does not pertain to the participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed Vaccine SAE Report Form is maintained in the investigator site file. Follow-up is conducted to obtain general information on the pregnancy and its outcome for all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth. In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by gross visual inspection (unless preprocedure test findings are conclusive for a congenital anomaly and the findings are reported). Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly), the investigator should follow the procedures for reporting SAEs. Additional information about pregnancy outcomes that are reported to Pfizer Safety as SAEs follows:
* Spontaneous abortion including miscarriage and missed abortion;
* Neonatal deaths that occur within 1 month of birth should be reported, without regard to causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs when the investigator assesses the infant death as related or possibly related to exposure to the study intervention. Additional information regarding the EDP may be requested by the sponsor. Further follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the participant with the Pregnant Partner Release of Information Form to deliver to his partner. The investigator must document in the source documents that the participant was given the Pregnant Partner Release of Information Form to provide to his partner.
220.127.116.11. Exposure During Breastfeeding An exposure during breastfeeding occurs if:
* A female participant is found to be breastfeeding while receiving or after discontinuing study intervention.
* A female is found to be breastfeeding while being exposed or having been exposed to study intervention (ie, environmental exposure). An example of environmental exposure during breastfeeding is a female family member or healthcare provider who reports that she is breastfeeding after having been exposed to the study intervention by inhalation or skin contact. The investigator must report exposure during breastfeeding to Pfizer Safety within 24 hours of the investigator’s awareness, irrespective of whether an SAE has occurred. The information must be reported using the Vaccine SAE Report Form. When exposure during breastfeeding occurs in the setting of environmental exposure, the exposure information does not pertain to the participant enrolled in the study, so the information is not recorded on a CRF. However, a copy of the completed Vaccine SAE Report Form is maintained in the investigator site file. An exposure during breastfeeding report is not created when a Pfizer drug specifically approved for use in breastfeeding women (eg, vitamins) is administered in accord with authorized use. However, if the infant experiences an SAE associated with such a drug, the SAE is reported together with the exposure during breastfeeding. Here’s the clear part of this, that everyone can understand:
18.104.22.168. Occupational Exposure An occupational exposure occurs when a person receives unplanned direct contact with the study intervention, which may or may not lead to the occurrence of an AE. Such persons may include healthcare providers, family members, and other roles that are involved in the trial participant’s care. The investigator must report occupational exposure to Pfizer Safety within 24 hours of the investigator’s awareness, regardless of whether there is an associated SAE. The information must be reported using the Vaccine SAE Report Form. Since the information does not pertain to a participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed Vaccine SAE Report Form is maintained in the investigator site file.
I WILL TRANSLATE THAT TO ENGLISH:
An occupational exposure occurs when a person receives unplanned direct contact with a vaccine test subject, which may or may not lead to the occurrence of an adverse event. These people may include health care providers, family members, and other people who are around the trial participant.
When such exposures happen, the investigator must report them to Pfizer safety within 24 hours of becoming aware of when they happened, regardless of whether or not there is an associated secondary adverse event. This must be reported using the vaccine secondary adverse event report form. SINCE THE INFORMATION DOES NOT PERTAIN TO A PARTICIPANT INVOLVED IN THE STUDY, THE INFORMATION WILL BE KEPT SEPARATE FROM THE STUDY.
My comment: This is why we have green screen Biden. They are ALL green screen now, we just caught Biden. They are green screen and working from sets because they have opened Pandora’s box and intend to hide out until everything is finished. This is why many people are claiming the white house is empty and that they are working from a set ad are not actually there. Because they are not there. If they do ever go on camera, they are not where they say they are. India is having their disaster happen now because they started with the vaxxes first, and have more people vaxxed than any other country.
“Coronaviruses” created with “gain of function”, that is, increased contagion, have been created in the Wuhan lab for years, and are genetically engineered bioweapons.
The NIH with Fauci and the new administration, are now again funding the Wuhan laboratory to develop more of these genetically engineered bioweapons.
New ones are gradually released, creating the public perception that Injections (“vaccines”) are absolutely necessary. Very little information is given about the most important factor which is strengthening your immune system. This myth about the injections is a much more harmful perception than the current masking myth.
Now that the public has been widely influenced through the constant mass media narrative and propaganda, the government has also paved the way for the rollout of Bill Gate’s “Covid-19 vaccines”. This coordinated plan goes all the way back to the Trump administration. This is the next step in the “Georgia Guide-Stones” depopulation plan. These injections are mRNA weapons of mass destruction.
However, there is another highly possible future development, not foreseen by Gates and his psychopathic globalist partners. In the video link below at Brighteon,
Here comes the magical vagina overplaying her Trump support hand with her prepared script. Ask yourselves…why did Mata Hari feel the need to have this uploaded today after the internet went wild with speculations on how the Trump team contracted COVID-19? Who was close enough to everyone…who had access…who is being overlooked?
She reminds you that she previously contracted COVID, which is to subtly say that she could not have been infected in this latest round because she already had it. Then why didn’t Don Jr. contract it from his paramour? Or is she creating a narrative to distract you from seeing that she positioned herself into the Trump family for nefarious purposes?
Also notice that her video is not uploaded by the Trump campaign where she is supposed to be ‘working’; instead it is uploaded to the propaganda site The Hill, original home of John Solomon until we busted his chops for being an agent of the Privy Council (or the Pilgrims..or the Queen..or the Rothschilds).
So we went to see if she is still with the Trump team and headed over for a quickie on Wikipedia, home of revisionist history. We were blown away with this statement:
Sure enough Kim has been a naughty hussy. She was alleged to be showing penis pictures to her work colleagues. (One wonders whose dicks were so special to pass around for all to see- Don’s, Gavin’s, Epstein’s itsy bitsy one, or Anthony’s wiener?)
“The complaint said that Guilfoyle showed the assistant photographs of male genitalia, belonging to men with whom she had sexual relations, and that she “spoke incessantly and luridly about her sex life.””
All references of her being a “special member” or “top Trump aide” have disappeared on the Wikipedia page and other sites that we checked. So clearly, someone is scrubbing her association with the Trump campaign.
Cleverness, training, character, and patriotism are often no defense against a well-set honey trap. And as in normal life, no planning can take into account that a romance begun in deceit might actually turn into a genuine, passionate affair. In fact, when an East German honey trap was exposed in 1997, one of the women involved refused to believe she had been deceived, even when presented with the evidence. “No, that’s not true,” she insisted. “He really loved me.”
Get ready, patriots. They are teeing up Joe for removal and replacement. Of course, they will blame President Trump for his COVID death. There will be a huge funeral, hoping for the martyrdom vote. Who knows if Joe will actually be in the casket. He could be placed in a private wing of a dementia care facility.
No one will really know. But Kamala will be ready to jump into his position. (If Titter says this tweet is not available to you, click ‘enter’ a few times until it appears.)
Remember…Kamala Harris is not eligible to hold the office of president…and Hillary Clinton knows this. Don’t think for a minute that Hildabeast won’t use this info weapon to knock Kamala off the ticket.
Includes numerous conflicting relationships with Goldman Sachs, J.P. Morgan, Wellcome Trust (GlaxoSmithKline – GSK), Harvard, UPenn, Stanford, Merck, Novartis, Sanofi, McKinsey, London School of Economics (notorious promoter of communist ideology), Medtronic, MIT, Dell, Roche, Hoffman-Roche, VMware,
Moderna’s CEO Stephane Bancel and Chief Medical Officer Tal Zaks, MD, Phd have been big stock sellers for a year. Zaks was director of clinical development and translational medice for GLAXOSMITHKLINE (Wellcome Trust – co-owner of the Coronavisur Patent along with the Gates Foundation. THIS CONFLICT IS ALONE IS DISQUALIFYING & FRAUDULENT GIVE GLAXO’S RELATIONSHIP WITH THE PIRBRIGHT INSTITUTE (UK). https://heightzone.com/dr-tal-zaks/
Israeli Tal Zaks – Been only selling his Moderna stock (dumping) since Dec. 2019
This guy is evidently dumping his Moderna shares while he is promoting his supposed COVID vaccine.
That is illegal stock manipulation and should land him and his CEO in jail.
IRS No.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38753 | Film No.: 20787049
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences
Executives, non-executive directors and director nominee
The following table sets forth the name, age and position of each of our executives, non-executive directors and director nominee as of March 2, 2020.
Stéphane Bancel (1)
Chief Executive Officer and Director
Juan Andres (1)
Chief Technical Operations and Quality Officer
Chief Digital and Operational Excellence Officer
Chief Human Resources Officer
Lori Henderson, J.D. (1)
General Counsel and Corporate Secretary
Stephen Hoge, M.D. (1)
Lorence Kim, M.D. (1)
Chief Financial Officer
Tal Zaks, M.D., Ph.D. (1)
Chief Medical Officer
Noubar B. Afeyan, Ph.D. (4)(5)
Stephen Berenson (2)(3)
Robert Langer, Sc.D. (4)
Elizabeth Nabel, M.D. (4)(5)
François Nader, M.D.(5)
Paul Sagan (2)(3)
Moncef Slaoui, Ph.D.(5)
Sandra Horning, M.D.
Member of the Audit Committee
Member of the Compensation and Talent Committee
Member of the Nominating and Corporate Governance Committee
Member of the Product Development Committee
These relationships alone should fundamentally disqualify Moderna or any of its INTERLOCKING relationships from any involvement in Coronavirus.
“Since we nominated our first program in late 2014, we and our strategic collaborators have advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another 3 have open INDs. Our therapeutic and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. We have assembled an exceptional team of approximately 700 employees and have established strategic alliances with leading biopharmaceutical companies, including AstraZeneca, Merck & Co., and Vertex Pharmaceuticals, as well as government-sponsored and private organizations focused on global health initiatives, including Biomedical Advanced Research and Development Authority, or BARDA, Defense Advanced Research Projects Agency, or DARPA, and the Bill & Melinda Gates Foundation. As of September 30, 2018, we have raised over $2.6 billion in total funding from our strategic collaborators and investors, and have cash, cash equivalents, and investments of $1.2 billion. As we unlock the inherent advantages of mRNA, we aim to address as many diseases and impact as many patients as our technology, talent, and capital permit.”
Stéphane Bancel has served as our Chief Executive Officer since October 2011 and a member of our board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA (Euronext: BIM). From July 2000 to March 2006, he served in various roles at Eli Lilly and Company (NYSE: LLY), including as Managing Director, Belgium, and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly and Company, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux. Mr. Bancel currently serves on the board of directors of Qiagen N.V. (NYSE: QGEN) and previously served on the boards of directors of BG Medicine, Inc. (OTCMKTS: BGMD) and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School. We believe that Mr. Bancel is qualified to serve on our board of directors because of his extensive leadership experience in the healthcare industry and experience as a director of public and private companies.
Juan Andres joined the Company in August 2017, and has served as our Chief Technical Operations and Quality Officer since August 2018. Before joining the Company, Mr. Andres worked at Novartis AG (NYSE: NVS) from
2005 to 2017, in various roles of increasing responsibility including serving as Global Head, Technical Operations (Manufacturing and Supply Chain), Global Head of Quality, and Global Head of Technical Research and Development. From 1987 to 1996, Mr. Andres served in various manufacturing, production, and quality roles at Eli Lilly and Company (NYSE: LLY), including as Vice President, Pharmaceutical Manufacturing. Mr. Andes has served as a member of the board of directors of Evelo Biosciences, Inc. (Nasdaq: EVLO) since December 2019, and of Avantor, Inc. (NYSE: AVTR), since September 2019. Mr. Andres obtained a degree in pharmacy at the Universidad de Alcalá in Spain.
Marcello Damiani joined the Company in May 2015, and has served as our Chief Digital and Operational Excellence Officer since September 2018. From 2009 to 2015, Mr. Damiani held senior roles at bioMérieux (Euronext: BIM), including Senior Vice President and Group Chief Information Officer. Mr. Damiani holds an M.S. degree in Information Systems Architecture from the University of Toulouse, France and completed an international Executive M.B.A. program through TRIUM, an alliance of the London School of Economics, the NYU Stern Business School, and the HEC Paris School of Management, France.
Tracey Franklin has served as our Chief Human Resources Officer since October 2019. From 2004 to October 2019, Ms. Franklin held positions of increasing responsibility at Merck & Co., Inc., including most recently Vice President, HR Chief Talent and Strategy Officer. Ms. Franklin holds a B.A. in communication arts and sciences from Pennsylvania State University and a Masters in industrial and organizational psychology from Fairleigh Dickinson University.
Lori Henderson, J.D., has served as our General Counsel and Corporate Secretary since April 2018. From 2011 to 2018, Ms. Henderson served at Albany Molecular Research Inc. (Nasdaq: AMRI) first as Vice President, General Counsel and Corporate Secretary until 2014 and then as Senior Vice President, General Counsel and Head of Business Development. Prior to her time at AMRI, Ms. Henderson worked as a corporate attorney at Goodwin Procter LLP and as a General Counsel at other corporations. She received her J.D. from the George Washington University Law School and her B.A. in Business and Economics from Gordon College.
Stephen Hoge, M.D., joined the Company in January 2013 and has served as our President since February 2015. From 2010 to 2012, Dr. Hoge was a Partner at McKinsey & Company and a leader in the firm’s healthcare practice. From 2005 to 2010, he served in roles of increasing responsibility at McKinsey & Company. From 2004 to 2005, Dr. Hoge was a resident physician at New York University/Bellevue Hospital. Dr. Hoge has served on the board of directors of Axcella Health, Inc. (Nasdaq: AXLA). He received an M.D. from the University of California, San Francisco and a B.A. in neuroscience from Amherst College.
Lorence Kim, M.D., has served as our Chief Financial Officer since April 2014. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently as a Managing Director and co-head of biotechnology investment banking. Dr. Kim has served on the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) since 2014. He received an A.B. in Biochemical Sciences from Harvard University, an M.B.A. in Healthcare Management from the Wharton School of the University of Pennsylvania, and an M.D. from the University of Pennsylvania School of Medicine.
Tal Zaks, M.D., Ph.D., has served as our Chief Medical Officer since March 2015. Prior to joining the Company, Dr. Zaks served in senior development positions at Sanofi (NYSE: SNY) from 2010 to 2015, including Senior Vice President and Head of Global Oncology. From July 2008 to May 2010, he served as Vice President of Clinical Research, Oncology at Cephalon. Prior to this, Dr. Zaks spent four years at GlaxoSmithKline (NYSE: GSK) as Director, Clinical Development and Translational Medicine and three years at the National Cancer Institute as a Postdoctoral Fellow. He is currently an Associate Professor of Medicine at the University of Pennsylvania and serves on the board of directors of Adaptimmune Therapeutics plc (Nasdaq: ADAP). Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.
Noubar B. Afeyan, Ph.D., is a co-founder and has served on our board of directors since incorporation, and has served as a chairman of our board of directors since February 2012. In 1999, Dr. Afeyan founded Flagship Pioneering and serves as its Senior Managing Partner and Chief Executive Officer. Since April 2013, Dr. Afeyan has served on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY) and since October 2010, on the board of Seres Therapeutics, Inc. (Nasdaq: MCRB). He currently serves on the boards of numerous privately held companies, and has previously served on the boards of numerous privately and publicly held companies, including Evelo Biosciences, Inc. (Nasdaq: EVLO), Kaleido Biosciences, Inc. (Nasdaq: KLDO) and BG Medicine, Inc (OTCMKTS: BGMD). He received a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology (“MIT”) and a B.S. in chemical engineering from McGill University. Dr. Afeyan is currently a visiting lecturer of business administration at Harvard Business School and was previously a senior lecturer at MIT’s Sloan School of Management where he taught courses on technology-entrepreneurship, innovation, and leadership. We believe that Dr. Afeyan’s significant experience co-founding, leading, and investing in numerous biotechnology companies make him qualified to serve on our board of directors.
Stephen Berenson has served as a member of our board of directors since October 2017. Mr. Berenson is a Managing Partner at Flagship Pioneering. Prior to that, Mr. Berenson spent 33 years as an investment banker at J.P. Morgan. During his last twelve years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking and focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was co-founder of J.P. Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. Mr. Berenson also serves as Chairman of the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) and on the board of directors of CiBO Technologies, Inc. Mr. Berenson received an S.B. in mathematics from MIT. We believe that Mr. Berenson is qualified to serve on our board of directors because of his experience in the banking and investment industries.
Robert Langer, Sc.D., has served as a member of our board of directors since December 2010. Dr. Langer has been an Institute Professor at MIT since 2005, and prior to that was a Professor at MIT beginning in 1977. Dr. Langer currently serves on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY), Kala Pharmaceuticals, Inc. (Nasdaq: KALA), and the UK public company Puretech Health plc (LON: PRTC), and previously served on the board of directors of Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), Wyeth (NYSE: WYE), Fibrocell Science, Inc. (Nasdaq: FCSC) and Millipore Corporation (acquired by Merck KGaA in 2010). Dr. Langer also served as a member of the Science Board to the U.S. Food and Drug Administration from 1995 to 2002, including his service as chairman from 1999 to 2002. Dr. Langer received his B.S. from Cornell University and his Sc.D. from MIT, both in Chemical Engineering. We believe that Dr. Langer is qualified to serve on our board of directors because of his pioneering academic work, extensive medical and scientific knowledge and experience, and his previous service on public company boards of directors.
Elizabeth Nabel, M.D., has served as a member of our board of directors since December 2015. Dr. Nabel has served as President of Harvard University-affiliated Brigham Health, which includes Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, and the Brigham and Women’s Physician Organization, since 2010. Dr. Nabel has also been a Professor of Medicine at Harvard Medical School since 2010. Prior to that, Dr. Nabel held a variety of roles, including Director, at the National Heart, Lung and Blood Institute at the National Institutes of Health, a federal agency funding research, training and education programs to promote the prevention and treatment of heart, lung and blood diseases, from 1999 to 2009. She is an elected member of the National Academy of Medicine of the National Academy of Sciences. Dr. Nabel currently serves on the board of directors of Medtronic plc (NYSE: MDT) and as a trustee of Tekla Capital Management LLC. We believe that Dr. Nabel is qualified to serve on our board of directors because of her extensive experience in the health care field, including senior positions with a number of research universities and organizations.
François Nader, M.D., has served as a member of our board of directors since December 2019. Dr. Nader currently serves as Chairman of the board of directors of Acceleron Pharma Inc. (Nasdaq: XLRN), Prevail
Therapeutics Inc. (Nasdaq: PRVL) and Talaris Therapeutics, Inc. He also serves on the board of directors of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and as an advisor for SVB Leerink. Dr. Nader is the past Chairman of BioNJ, New Jersey’s biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization (BIO), NPS Pharmaceuticals (Nasdaq: NPSP), Advanced Accelerator Applications S.A. (Nasdaq: AAAP), Baxalta Inc. (NYSE: BXLT), Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), Trevena Inc. (Nasdaq: TRVN) and Noven Pharmaceuticals Inc. (Nasdaq: NOVN). Dr. Nader earned his French doctorate in medicine from St. Joseph University in Lebanon and a physician executive M.B.A. from the University of Tennessee. We believe that Dr. Nader is qualified to serve on our board of directors because of his experience in integrated healthcare markets and medical and regulatory affairs and his service on numerous boards of directors.
Israel Ruiz has served as a member of our board of directors since February 2017. Mr. Ruiz has been the Executive Vice President and Treasurer at MIT since 2011. In this role, Mr. Ruiz oversees all principal administrative and financial functions of MIT. Prior to his current role, Mr. Ruiz served as the Vice President for Finance for MIT from 2007 to 2011 and as a principal for MIT’s Office of Budget and Financial Planning from 2001 to 2007. He currently serves on the board of directors of FM Global and previously served on the board of directors of Fortive Corporation (NYSE: FTV). Mr. Ruiz received a degree in industrial and mechanical engineering from the Polytechnic University of Catalonia and a master’s degree from the MIT Sloan School of Management. We believe that Mr. Ruiz is qualified to serve on our board of directors because of his deep financial and accounting experience as the chief financial officer of MIT.
Paul Sagan has served as a member of our board of directors since June 2018. Mr. Sagan has been a Managing Director at General Catalyst Partners, a venture capital firm, since January 2018, and previously served as an Executive In Residence (XIR) since January 2014. From April 2005 to January 2013, Mr. Sagan served as Chief Executive Officer at Akamai Technologies, Inc. (Nasdaq: AKAM) and was President from May 1999 to September 2010 and from October 2011 to January 2013. He was also a director of Akamai Technologies until 2019. Mr. Sagan currently serves on the board of directors of VMware, Inc. (NYSE: VMW) and was a director of EMC from December 2007 until the acquisition by Dell, Inc. in September 2016. Mr. Sagan received his B.S. from the Medill School of Journalism at Northwestern University. We believe that Mr. Sagan is qualified to serve on our board of directors because of his experience and leadership both in the technology and venture capital fields.
Moncef Slaoui, Ph.D., has served as a member of our board of directors since July 2017. Dr. Slaoui joined GlaxoSmithKline Plc (NYSE: GSK) (“GSK”) in 1988, where he engineered the development of a robust vaccines pipeline. He then led worldwide business development for pharmaceutical products before his appointment to lead research and development in 2006. He assumed overall responsibility for GSK’s Oncology Business in 2010, for GSK Vaccines in 2011, and for all Global Franchises in 2012. Dr. Slaoui is Chairman of the board of directors of Galvani Bioelectronics, a company launched in November 2016 that GSK jointly owns with Verily Life Sciences. Dr. Slaoui has advised the U.S. President’s Council of Advisors on Science and Technology, was a member of the Board of the Agency for Science, Technology, & Research until January 2011, the PhRMA Foundation Board from 2008 to 2016, and the Advisory Committee to the Director of the National Institutes of Health from 2011 to 2016. Dr. Slaoui previously served on the board of directors of Intellia Therapeutics Inc. (Nasdaq: NTLA). Dr. Slaoui is also a former Professor of Immunology at the University of Mons, Belgium. Dr. Slaoui received a Ph.D. in Molecular Biology and Immunology from Université Libre de Bruxelles. We believe that Dr. Slaoui is qualified to serve on our board of directors because of his vast experience in the pharmaceutical industry and various leadership positions.
Sandra Horning, M.D., is nominated to serve as a Class II director on our board. Dr. Horning was the Chief Medical Officer and Global Head of Product Development of Roche, Inc., from 2009 until her retirement in 2019. Prior to Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at the Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to
2006, she served as President of the American Society of Clinical Oncology. From 2015 to 2018, Dr. Horning served on the Foundation Medicine Board of Directors. She currently serves as an advisor to EQRx, Inc. Dr. Horning received her M.D. from the University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University. We believe that Dr. Horning is qualified to serve on our board of directors because of her significant experience in the field of oncology and her product development leadership experience.
. . . . . . .
This financial disclosure is from Moderna’s Initial Public Offering (S-1) disclosure filed on Nov. 09, 2018.
It shows the interlocking and seditious relationships that disqualify ALL of these actors in the current Coronavirus Scam-demic… Gates Foundation, DARPA, BARDA, Merck, AstraZeneca (ICI, British government, Queen’s Golden Share) and Moderna’s Israeli chief medical officer Tal Zaks who was a clinical director at GlaxoSmithKline (Wellcome Trust, agent of the Pilgrims Society and the Queen’s Privy Council)
I researched some of the “facts” going around claiming to have “debunked” the movie, which are being regurgitated by many who prefer to remain asleep and won’t put the effort in to research things themselves. Here is what I found along with all of my supporting sources.
Dr. Anthony Fauci has worked at the National Institute of Health (NIH) since 1968 and has been a Director with the organization since 1984, “both as a scientist and as the head of the NIAID at the NIH”. A simple Wikipedia search resolved that one.
The NIH was one of the institutions funding the original study published in 10/23/2009, which Dr. Mikovits participated in and makes reference to in the Plandemic movie. Dr. Fauci worked at and continues to work at the NIH, one of the primary financial contributors to the study as one of it’s most senior directors, so you can indeed say that Dr. Judy Mikovits was in fact working for Dr. Fauci. I have downloaded the complete original study and saved for you to access here (highlights on page 3 denote Dr. Judy Mikovits’s participation and her employing firm) (highlights on page 6 indicate the institutions which provided the funding for the study):
The study was challenged in 2010, when other researches could not replicate their findings and in September 2010, the original team, inclusive of Dr. Judy Mikovits issued an official response supporting their work.
After which the original study was partially and then subsequently fully retracted (a very rare move in science). The partial retraction document states that two of the co-authors, Robert Silverman and Das Gupta (whom the original study listed as working for the Department of Cancer Biology) re-analyzed the samples they used and discovered that they had been contaminated. Please refer back to the first link provided herein, for item #1 showing the original study, indicates on the document that it has since been retracted.
That she was arrested and a quote from the prosecuting district attorney, that said the charges were dropped because “there were issues with the witnesses”.
In September 2012, Dr. Judy Mikovits and a team of other scientists conducted another study replicating the original one and published their findings, ultimately resolving the scientific communities dispute over the original work.
As previously shared in another post, Dr. Fauci does in fact hold a large number of patents related to HIV (as Dr. Judy Mikovits states in the video). He also holds numerous patents related to the Novel Coronavirus.
Also as previously shared in another post, the polio vaccines the Bill and Melinda Gates Foundation tested on children in the Africa, causing an outbreak of Polio from the vaccine itself and paralysis on the children.
PUBLIC ALERT: Microsoft just filed for a patent to tie your cellular activity to your approval to buy and sell with cryptocurrency – application assigned to a patent examining newbie with NO EXPERIENCE by British SERCO.
Send demands to your elected representatives, media, White House and Microsoft itself to stop this outrageously evil patent application.
Jahed Ali, the patent examiner assigned is a total newbie with NO HISTORY.